throbber
—DOSAGE FORMS AND STRENGTHS
`500 mg lyophilized powder for reconstitution in a single-use vial (3)
`
`0
`
`0
`
`0
`
`0
`
`0
`
`0
`
`0
`
`0
`
`0
`
`TCONTRAINDICATIONS
`Known hypersensitivity to daptomycin (4)
`
`WARNINGS AND PRECAUTIONST
`Anaphylaxis/hypersensitivity reactions (including life-threatening):
`Discontinue CUBICIN and treat signs/symptoms. (5.1)
`Myopathy and rhabdomyolysis: Monitor CPK levels and follow muscle
`pain or weakness; if elevated CPK or myopathy occurs, consider
`discontinuation of CUBICIN. (5.2)
`Eosinophilic pneumonia: Discontinue CUBICIN and consider treatment
`with systemic steroids. (5.3)
`Peripheral neuropathy: Monitor for neuropathy and consider
`discontinuation (5.4)
`Potential nervous system and/or muscular system effects in pediatric
`patients younger than 12 months: Avoid use of CUBICIN in this age
`group. (5.5)
`Clostridium difl?cile—associated diarrhea: Evaluate patients if diarrhea
`occurs. (5.6)
`Persisting or relapsing S. aureus bacteremia/endocarditis: Perform
`susceptibility testing and rule out sequestered foci of infection. (5.7)
`Decreased efficacy was observed in patients with moderate baseline
`renal impairment. (5.8)
`
`ADVERSE REACTIONS—
`The most clinically significant adverse reactions observed with CUBICIN
`4 mg/kg (cSSSI trials) and 6 mg/kg (S. aureus bacteremia/endocarditis trial)
`were abnormal liver function tests, elevated CPK, and dyspnea. (6.1)
`
`To report SUSPECTED ADVERSE REACTIONS, contact Cubist
`Pharmaceuticals, Inc., at 1-877-282-4786 or FDA at 1-800-FDA-
`1088 or www.fda.gov/medwatch.
`
`See 17 for PATIENT COUNSELING INFORMATION
`
`Revised: 11/2014
`
`5.10 Non-Susceptible Microorganisms
`6 ADVERSE REACTIONS
`6.1
`Clinical Trials Experience
`6.2
`Post-Marketing Experience
`7 DRUG INTERACTIONS
`7.1
`HIVIG-CoA Reductase Inhibitors
`7.2 Drug-Laboratory Test Interactions
`8 USE IN SPECIFIC POPULATIONS
`8.1
`Pregnancy
`8.3 Nursing Mothers
`8.4
`Pediatric Use
`8.5
`Geriatric Use
`8.6
`Patients with Renal Impairment
`10 OVERDOSAGE
`11 DESCRIPTION
`12 CLINICAL PHARMACOLOGY
`12.1 Mechanism of Action
`12.2 Pharmacodynamics
`12.3 Pharmacokinetics
`12.4 Microbiology
`13 NONCLINICAL TOXICOLOGY
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`13.2 Animal Toxicology and/or Pharmacology
`14 CLINICAL TRIALS
`14.1 Complicated Skin and Skin Structure Infections
`14.2 S. aureus Bacteremia/Endocarditis
`15 REFERENCES
`16 HOW SUPPLIED/STORAGE AND HANDLING
`17 PATIENT COUNSELING INFORMATION
`
`* Sections or subsections omitted from the full prescribing information are not
`listed
`
`CUBIST 2001
`
`FRESENIUS-KABI V. CUBIST
`
`IPR20l5-01570
`
`HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use
`CUBICIN® safely and effectively. See full prescribing information for
`CUBICIN.
`
`CUBICIN® (daptomycin for injection) for Intravenous Use
`Initial U.S. Approval: 2003
`
`TTLRECENT MAJOR CHANGESTTT
`
`Warnings and Precautions (5.5)
`
`11/2014
`
`To reduce the development of drug-resistant bacteria and maintain the
`effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be
`used to treat infections that are proven or strongly suspected to be caused by
`bacteria.
`
`TINDICATIONS AND USAGE
`CUBICIN is a lipopeptide antibacterial indicated for the treatment of:
`0
`Complicated skin and skin structure infections (cSSSI) (1.1)
`0
`Staphylococcus aureus bloodstream infections (bacteremia), including
`those with right-sided infective endocarditis (1.2)
`CUBICIN is not indicated for the treatment ofpneumonia. (1.3)
`
`0
`
`DOSAGE AND ADMINISTRATIONTTT
`Recommended dosage regimen for adult patients (2.2, 2.3, 2.4):
`Dosage Regimen
`S. aureus Bacteremia
`For 2 to 6 weeks
`
`C1-eatm(]g:CRl)earance
`C
`
`cSSSI
`For 7 to 14 da s
`
` 0
`
`24 hours
`
`24 hours
`
`48 hours*
`48 hours*
`hemodialysis and CAPD
`* Administered following hemodialysis on hemodialysis days.
`0
`Administered intravenously in 0.9% sodium chloride, either by injection
`over a 2-minute period or by infusion over a 30-minute period. (2.1, 2.5)
`Do not use in conjunction with ReadyMED® elastomeric infusion pumps.
`(2-7)
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`
`1
`
`INDICATIONS AND USAGE
`1.1
`Complicated Skin and Skin Structure Infections
`1.2
`Staphylococcus aureus Bloodstream Infections (Bacteremia),
`Including Those with Right-Sided Infective Endocarditis, Caused
`by Methicillin-Susceptible and Methicillin-Resistant Isolates
`Limitations of Use
`1.3
`1.4 Usage
`2 DOSAGE AND ADMINISTRATION
`2.1
`Administration Duration
`2.2
`Complicated Skin and Skin Structure Infections
`2.3
`Staphylococcus aureus Bloodstream Infections (Bacteremia),
`Including Those with Right-Sided Infective Endocarditis, Caused
`by Methicillin-Susceptible and Methicillin-Resistant Isolates
`Patients with Renal Impairment
`2.4
`Preparation of CUBICIN for Administration
`2.5
`Compatible Intravenous Solutions
`2.6
`Incompatibilities
`2.7
`3 DOSAGE FORMS AND STRENGTHS
`4 CONTRAINDICATIONS
`5 WARNINGS AND PRECAUTIONS
`5 .1
`Anaphylaxis/Hypersensitivity Reactions
`5.2 Myopathy and Rhabdomyolysis
`5.3
`Eosinophilic Pneumonia
`5 .4
`Peripheral Neuropathy
`5.5
`Potential Nervous System and/or Muscular System Effects in
`Pediatric Patients Younger than 12 Months
`5.6 Clostridium difl‘icile—Associated Diarrhea
`5.7
`Persisting or Relapsing S. aureus Bacteremia/Endocarditis
`5.8 Decreased Efficacy in Patients with Moderate Baseline Renal
`Impairment
`5.9 Drug-Laboratory Test Interactions
`
`Reference ID: 3664681
`
`

`
`FULL PRESCRIBING INFORMATION
`
`CUBICIN® (daptomycin for injection)
`
`1
`
`INDICATIONS AND USAGE
`
`CUBICIN is indicated for the treatment of the infections listed below.
`
`1.1
`
`Complicated Skin and Skin Structure Infections
`
`Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the
`following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant
`isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp.
`equisimilis, and Enterococcusfaecalis (vancomycin-susceptible isolates only).
`
`1.2
`
`Staphylococcus aureus Bloodstream Infections (Bacteremia), Including
`Those with Right-Sided lnfective Endocarditis, Caused by Methici||in-
`Susceptible and Methicillin-Resistant Isolates
`
`Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided
`infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.
`
`1.3
`
`Limitations of Use
`
`CUBICIN is not indicated for the treatment of pneumonia.
`
`CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus.
`
`The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included lin1ited
`data fiom patients with left-sided infective endocarditis; outcomes in these patients were poor
`[see Clinical Trials (I 4. 2)]. CUBICIN has not been studied in patients with prosthetic valve
`endocarditis.
`
`1.4
`
`Usage
`
`Appropriate specimens for microbiological examination should be obtained in order to isolate
`and identify the causative pathogens and to determine their susceptibility to daptomycin.
`
`To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN
`and other antibacterial drugs, CUBICIN should be used only to treat infections that are proven or
`strongly suspected to be caused by susceptible bacteria.
`
`When culture and susceptibility information is available, it should be considered in selecting or
`modifying antibacterial therapy. In the absence of such data, local epidemiology and
`susceptibility patterns may contribute to the empiric selection of therapy. Empiric therapy may
`be initiated while awaiting test results.
`
`Reference ID: 3664681
`
`

`
`2
`
`DOSAGE AND ADMINISTRATION
`
`2.1
`
`Administration Duration
`
`CUBICIN should be administered intravenously either by injection over a two (2) minute period
`or by infusion over a thirty (30) minute period.
`
`2.2
`
`Complicated Skin and Skin Structure Infections
`
`CUBICIN 4 mg/kg should be administered intravenously in 0.9% sodium chloride injection once
`every 24 hours for 7 to 14 days.
`
`2.3
`
`Staphylococcus aureus Bloodstream Infections (Bacteremia), Including
`Those with Right-Sided lnfective Endocarditis, Caused by Methici||in-
`Susceptible and Methicillin-Resistant Isolates
`
`CUBICIN 6 mg/kg should be administered intravenously in 0.9% sodium chloride injection once
`every 24 hours for 2 to 6 weeks. There are limited safety data for the use of CUBICIN for more
`than 28 days of therapy. In the Phase 3 trial, there were a total of 14 patients who were treated
`with CUBICIN for more than 28 days.
`
`2.4
`
`Patients with Renal Impairment
`
`The recommended dosage regimen for patients with creatinine clearance (CLCR) <30 mL/min,
`including patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), is 4
`
`‘ mg/kg (cSSSI) or 6 mg/kg (S. aureus bloodstream infections) once every 48 hours (Table liliable
`
`-1-). When possible, CUBICIN should be administered following the completion of hemodialysis
`on hemodialysis days [see Warnings and Precautions (5.2, 5.8), Use in Specific Populations
`(8.6), and Clinical Pharmacology (I2.3)].
`
`Table 1. Recommended Dosage of CUBICIN in Adult Patients
`
`Creatinine Clearance
`
`Dosage Regimen
`
`(CLCR) S. aureus Bloodstream Infections 230 mL/min
`
`<30 mL/mir1, including
`hemodialysis and CAPD
`
`4 mg/kg once every 24 hours
`
`6 mg/kg once every 24 hours
`
`4 mg/kg once every 48 hours*
`
`6 mg/kg once every 48 hours*
`
`* When possible, administer CUBICIN following the completion of hemodialysis on hemodialysis days.
`
`2.5
`
`Preparation of CUBICIN for Administration
`
`CUBICIN is supplied in single-use vials, each containing 500 mg daptomycin as a sterile,
`lyophilized powder. The contents of a CUBICIN vial should be reconstituted, using aseptic
`technique, to 50 mg/mL as follows:
`
`Note: To minimize foaming, AVOID vigorous agitation or shaking of the vial during or after
`reconstitution.
`
`Reference ID: 3664681
`
`

`
`1. Remove the polypropylene flip-off cap from the CUBICIN vial to expose the central
`portion of the rubber stopper.
`
`2. Slowly transfer 10 mL of 0.9% sodium chloride injection through the center of the
`rubber stopper into the CUBICIN vial, pointing the transfer needle toward the wall of
`the vial.
`
`3. Ensure that all of the CUBICIN powder is wetted by gently rotating the vial.
`
`4. Allow the wetted product to stand undisturbed for 10 minutes.
`
`Gently rotate or swirl the vial contents for a few minutes, as needed, to obtain a
`completely reconstituted solution.
`
`For intravenous (IV) injection over a period of 2 minutes, administer the appropriate volume of
`the reconstituted CUBICIN (concentration of 50 mg/mL).
`
`For IV infusion over a period of 30 minutes, the appropriate volume of the reconstituted
`CUBICIN (concentration of 50 mg/mL) should be further diluted, using aseptic technique, into a
`50 mL IV infusion bag containing 0.9% sodium chloride injection.
`
`Parenteral drug products should be inspected visually for particulate matter prior to
`administration.
`
`No preservative or bacteriostatic agent is present in this product. Aseptic technique must be used
`in the preparation of final IV solution. Stability studies have shown that the reconstituted
`solution is stable in the vial for 12 hours at room temperature and up to 48 hours if stored under
`
`refiigeration at 2 to 8°C (36 to 46°F).
`
`The diluted solution is stable in the infusion bag for 12 hours at room temperature and 48 hours
`if stored under refrigeration. The combined storage time (reconstituted solution in vial and
`diluted solution in infusion bag) should not exceed 12 hours at room temperature or 48 hours
`under refrigeration.
`
`CUBICIN vials are for single use only.
`
`2.6
`
`Compatible Intravenous Solutions
`
`CUBICIN is compatible with 0.9% sodium chloride injection and lactated Ringer’s injection.
`
`2.7
`
`lncompatibilities
`
`CUBICIN is not compatible with dextrose-containing diluents.
`
`CUBICIN should not be used in conjunction with ReadyMED® elastomeric lIlfiJSlOIl pumps
`(Cardinal Health, Inc.). Stability studies of CUBICIN solutions stored in ReadyMED®
`elastomeric infusion pumps identified an impurity (2-mercaptobenzothiazole) leaching fiom this
`pump system into the CUBICIN solution.
`
`Because only limited data are available on the compatibility of CUBICIN with other IV
`substances, additives and other medications should not be added to CUBICIN single-use vials or
`infusion bags, or infused simultaneously with CUBICIN through the same IV line. If the same
`IV line is used for sequential lIlfi1SlOIl of different drugs, the line should be flushed with a
`compatible intravenous solution before and after infusion with CUBICIN.
`
`Reference ID: 3664681
`
`

`
`3
`
`DOSAGE FORMS AND STRENGTHS
`
`500 mg daptomycin as a sterile, pale yellow to light brown lyophilized powder for reconstitution
`in a single-use vial.
`
`4
`
`CONTRAINDICATIONS
`
`CUBICIN is contraindicated in patients with known hypersensitivity to daptomycin.
`
`5
`
`WARNINGS AND PRECAUTIONS
`
`5.1
`
`Anaphy|axisIHypersensitivity Reactions
`
`Anaphylaxis/hypersensitivity reactions have been reported with the use of antibacterial agents,
`including CUBICIN, and may be life-threatening. If an allergic reaction to CUBICIN occurs,
`discontinue the drug and institute appropriate therapy [see Adverse Reactions (6.2)].
`
`5.2 Myopathy and Rhabdomyolysis
`
`Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in
`creatine phosphokinase (CPK) values to greater than 10 times the upper limit of normal (ULN),
`has been reported with the use of CUBICIN. Rhabdomyolysis, with or without acute renal
`failure, has been reported [see Adverse Reactions (6. 2)].
`
`Patients receiving CUBICIN should be monitored for the development of muscle pain or
`weakness, particularly of the distal extremities. In patients who receive CUBICIN, CPK levels
`should be monitored weekly, and more frequently in patients who received recent prior or
`concomitant therapy with an HMG-CoA reductase inhibitor or in whom elevations in CPK occur
`during treatment with CUBICIN.
`
`In patients with renal impairment, both renal function and CPK should be monitored more
`frequently than once weekly [see Use in Specific Populations (8. 6) and Clinical Pharmacology
`(I2.3)].
`
`In Phase 1 studies and Phase 2 clinical trials, CPK elevations appeared to be more frequent when
`CUBICIN was dosed more than once daily. Therefore, CUBICIN should not be dosed more
`frequently than once a day.
`
`CUBICIN should be discontinued in patients with unexplained signs and symptoms of myopathy
`in conjunction with CPK elevations to levels >l,000 U/L (~5>< ULN), and in patients without
`reported symptoms who have marked elevations in CPK, with levels >2,000 U/L (Zl0>< ULN).
`In addition, consideration should be given to suspending agents associated with rhabdomyolysis,
`such as HMG-CoA reductase inhibitors, temporarily in patients receiving CUBICIN [see Drug
`Interactions (7. 1)].
`
`5.3
`
`Eosinophilic Pneumonia
`
`Eosinophilic pneumonia has been reported in patients receiving CUBICIN [see Adverse
`Reactions (6. 2)]. In reported cases associated with CUBICIN, patients developed fever, dyspnea
`with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates. In general, patients
`developed eosinophilic pneumonia 2 to 4 weeks after starting CUBICIN and improved when
`
`Reference ID: 3664681
`
`

`
`CUBICIN was discontinued and steroid therapy was initiated. Recurrence of eosinophilic
`pneumonia upon re-exposure has been reported. Patients who develop these signs and symptoms
`while receiving CUBICIN should undergo prompt medical evaluation, and CUBICIN should be
`discontinued immediately. Treatment with systemic steroids is recommended.
`
`5.4
`
`Peripheral Neuropathy
`
`Cases of peripheral neuropathy have been reported during the CUBICIN postmarketing
`experience [see Adverse Reactions (6.2)]. Therefore, physicians should be alert to signs and
`symptoms of peripheral neuropathy in patients receiving CUBICIN.
`
`Potential Nervous System andlor Muscular System Effects in Pediatric
`5.5
`Patients Younger than 12 Months
`
`Avoid use of CUBICIN in pediatric patients younger than 12 months due to the risk of potential
`effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central)
`observed in neonatal dogs with intravenous daptomycin [see Nonclinical Toxicology (I3.2)].
`
`5.6
`
`Clostridium difficile-—Associated Diarrhea
`
`Clostridium difficile—associated diarrhea (CDAD) has been reported with the use of nearly all
`systemic antibacterial agents, including CUBICIN, and may range in severity from mild diarrhea
`to fatal colitis [see Adverse Reactions (6. 2)]. Treatment with antibacterial agents alters the
`normal flora of the colon, leading to overgrowth of C. diflicile.
`
`C. difficile produces toxins A and B, which contribute to the development of CDAD.
`Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, since these
`infections can be refiactory to antimicrobial therapy and may require colectomy. CDAD must be
`considered in all patients who present with diarrhea following antibacterial use. Careful medical
`history is necessary because CDAD has been reported to occur more than 2 months after the
`administration of antibacterial agents.
`
`If CDAD is suspected or confrrrned, ongoing antibacterial use not directed against C. difficile
`may need to be discontinued. Appropriate fluid and electrolyte management, protein
`supplementation, antibacterial treatment of C. diflicile, and surgical evaluation should be
`instituted as clinically indicated.
`
`5.7
`
`Persisting or Relapsing S. aureus BacteremiaIEndocarditis
`
`Patients with persisting or relapsing S. aureus bacteremia/endocarditis or poor clinical response
`should have repeat blood cultures. If a blood culture is positive for S. aureus, minimum
`inhibitory concentration (MIC) susceptibility testing of the isolate should be performed using a
`standardized procedure, and diagnostic evaluation of the patient should be performed to rule out
`sequestered foci of infection. Appropriate surgical intervention (e.g., debridement, removal of
`prosthetic devices, valve replacement surgery) and/or consideration of a change in antibacterial
`regimen may be required.
`
`Failure of treatment due to persisting or relapsing S. aureus bacteremia/endocarditis may be due
`to reduced daptomycin susceptibility (as evidenced by increasing MIC of the S. aureus isolate)
`[see Clinical Trials (I4.2)].
`
`Reference ID: 3664681
`
`

`
`5.8 Decreased Efficacy in Patients with Moderate Baseline Renal Impairment
`
`Limited data are available from the two Phase 3 complicated skin and skin structure infection
`(cSSSI) trials regarding clinical efficacy of CUBICIN treatment in patients with creatinine
`clearance (CLCR) <50 mL/min; only 31/534 (6%) patients treated with CUBICIN in the intent-to-
`treat (ITT) population had a baseline CLCR <50 mL/min. Table 2 shows the number of patients
`by renal function and treatment group who were clinical successes in the Phase 3 cSSSI trials.
`
`Table 2. Clinical Success Rates by Renal Function and Treatment Group in Phase 3 cSSSI Trials
`(Population: IT'I)
`
`20/35 (57%)
`
`Success Rate
`
`n/N (%)
`
`Comparator
`
`30/48 (63%)
`
`CUBICIN
`4 mg/kg q24h
`
`25/38 (66%)
`
`7/15 (47%)
`
`C
`
`LCR
`
`50-70 mL/miI1
`
`30—<50 mL/1I1in
`
`In a subgroup analysis of the ITT population in the Phase 3 S. aureus bacteremia/endocarditis
`trial, clinical success rates, as determined by a treatment-blinded Adjudication Committee [see
`Clinical Trials (I4.2)], in the CUBICIN-treated patients were lower in patients with baseline
`CLCR <50 mL/min (see Table 3). A decrease of the magnitude shown in Table 3 was not
`observed in comparator-treated patients.
`
`Table 3. Adjudication Committee Clinical Success Rates at Test of Cure by Baseline Creatinine Clearance
`and Treatment Subgroup in the S. aureus Bacteremia/Endocarditis Trial (Population: ITT)
`
`Success Rate
`
`n/N (%)
`
`Baseline CLCR
`
`CUBICIN
`6 mg/kg q24h
`
`Comparator
`
`1/1 (100%)
`
`Bacteremia
`
`30/50 (60%)
`12/26 (46%)
`2/14 (14%)
`
`Right-Sided
`Infective
`Endocarditis
`
`7/14 (50%)
`1/4 (25%)
`0/1 (0%)
`
`Bacteremia
`
`19/42 (45%)
`13/31 (42%)
`7/17 (41%)
`
`Right-Sided
`Infective
`Endocarditis
`
`5/11 (46%)
`1/2 (50%)
`
`Consider these data when selecting antibacterial therapy for use in patients with baseline
`moderate to severe renal impairment.
`
`Reference ID: 3664681
`
`

`
`5.9
`
`Drug-Laboratory Test Interactions
`
`Clinically relevant plasma concentrations of daptomycin have been observed to cause a
`significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of
`International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are
`utilized for the assay [see Drug-Laboratory Interactions (7. 2)].
`
`5.10 Non-Susceptible Microorganisms
`
`The use of antibacterials may promote the overgrowth of non-susceptible microorganisms. If
`superinfection occurs during therapy, appropriate measures should be taken.
`
`Prescribing CUBICIN in the absence of a proven or strongly suspected bacterial infection is
`unlikely to provide benefit to the patient and increases the risk of the development of drug-
`resistant bacteria.
`
`6
`
`ADVERSE REACTIONS
`
`The following adverse reactions are described, or described in greater detail, in other sections:
`
`- Anaphylaxis/hypersensitivity reactions [see Warnings and Precautions (5. 1)]
`
`- Myopathy and rhabdomyolysis [see Warnings and Precautions (5. 2)]
`
`- Eosinophilic pneumonia [see Warnings and Precautions (5. 3)]
`
`-
`
`-
`
`Peripheral neuropathy [see Warnings and Precautions (5. 4)]
`
`Increased International Normalized Ratio (INR)/prolonged prothrombin time [see
`Warnings and Precautions (5.9) and Drug-Laboratory Test Interactions (7. 2)]
`
`Because clinical trials are conducted under widely varying conditions, adverse reaction rates
`observed in the clinical trials of a drug carmot be directly compared with rates in the clinical
`trials of another drug and may not reflect the rates observed in practice.
`
`6.1
`
`Clinical Trials Experience
`
`Clinical trials enrolled 1,864 patients treated with CUBICIN and 1,416 treated with comparator.
`
`Complicated Skin and Skin Structure Infection Trials
`
`In Phase 3 complicated skin and skin structure infection (cSSSI) trials, CUBICIN was
`discontinued in 15/534 (2.8%) patients due to an adverse reaction, while comparator was
`discontinued in 17/558 (3.0%) patients.
`
`The rates of the most common adverse reactions, organized by body system, observed in cSSSI
`(4 mg/kg CUBICIN) patients are displayed in Table 4.
`
`Reference ID: 3664681
`
`

`
`Nervous system disorders ‘
`Headache
`Dizziness
`Skin/subcutaneous disorders
`
`Rash
`
`Diagnostic investigations
`Abnormal liver fimction tests
`
`Elevated CPK
`Infections
`
`Urinary tract infections
`Vascular disorders ‘
`Hypotension
`
`*
`
`-
`
`0.5
`
`1 .4
`
`
`
`Table 4. Incidence of Adverse Reactions that Occurred in 22% of Patients in the
`
`CUBICIN Treatment Group and 2 the Comparator Treatment Group in Phase 3
`cSSSI Trials
`
`Adverse Reacfim‘
`
`Gastrointestinal disorders
`
`Diarrhea
`
`Patients (%)
`
`CUBICIN 4 mg/kg
`(N=534)
`—
`
`Comparator*
`(N=558)
`
`4.3
`
`l\)U1 04>
`.
`
`3.8
`
`>—d>—d>—aONOOCN
`
`Respiratory disorders
`~
`Dyspnea
`Comparator: vancomycin (1 g IV q12h) or an anti-staphylococcal se1r1i-synthetic
`penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV
`in divided doses).
`
`Drug-related adverse reactions (possibly or probably drug-related) that occurred in <l% of
`patients receiving CUBICIN in the cSSSl trials are as follows:
`
`Body as a Whole.‘ fatigue, weakness, rigors, flushing, hypersensitivity
`
`Blood/Lymphatic System.‘ leukocytosis, thrombocytopenia, thrombocytosis, eosinophilia,
`increased International Normalized Ratio (INR)
`
`Cardiovascular System.‘ supraventricular arrhythmia
`
`Dermatologic System.‘ eczema
`
`Digestive System.‘ abdominal distension, stomatitis, jaundice, increased serum lactate
`dehydrogenase
`
`Metabolic/Nutritional System.‘ hypomagnesernia, increased serum bicarbonate, electrolyte
`disturbance
`
`Musculoskeletal System.‘ myalgia, muscle cramps, muscle weakness, arthralgia
`
`Nervous System.‘ vertigo, mental status change, paresthesia
`
`Reference ID: 3664681
`
`

`
`Special Senses.‘ taste disturbance, eye irritation
`
`S. aureus Bacteremia/Endocarditis Trial
`
`In the S. aureus bacteremia/endocarditis trial, CUBICIN was discontinued in 20/120 (16.7%)
`patients due to an adverse reaction, while comparator was discontinued in 21/116 (18.1%)
`patients.
`
`Serious Gram-negative infections (including bloodstream infections) were reported in 10/120
`(8.3%) CUBICIN-treated patients and 0/115 comparator-treated patients. Comparator-treated
`patients received dual therapy that included initial gentamicin for 4 days. Infections were
`reported during treatment and during early and late follow-up. Gram-negative infections
`included cholangitis, alcoholic pancreatitis, stemal osteomyelitis/mediastinitis, bowel infarction,
`recurrent Crohn’s disease, recurrent line sepsis, and recurrent urosepsis caused by a number of
`different Gram-negative bacteria.
`
`The rates of the most common adverse reactions, organized by System Organ Class (SOC),
`observed in S. aureus bacteremia/endocarditis (6 mg/kg CUBICIN) patients are displayed in
`Table 5.
`
`Table 5. Incidence of Adverse Reactions that Occurred in 25% of Patients in the CUBICIN
`
`Treatment Group and 2 the Comparator Treatment Group in the S. aureus
`Bacteremia/Endocarditis Trial
`
`Adverse Reaction*
`
`Patients
`
`n (%)
`
`CUBICIN 6 mg/kg
`(N=120)
`Infections and infestations ‘
`Sepsis NOS
`Bacteremia
`Gastrointestinal disorders ‘
`Abdominal pain NOS
`General disorders and administration site
`conditions
`
`Chest pain
`
`Edema NOS
`
`8 (7%)
`
`8 (7%)
`
`disorders
`
`Respiratory, thoracic and mediastinal ‘
`Pharyngolaryngeal pain
`Skin and subcutaneous tissue disorders ‘
`Pmmus
`Sweating increased
`Psychiatric disorders
`
`Insorrmia
`ll (9%)
`Investigations ‘
`Blood creatine phosphokinase increased
`8 (7%)
`
`Comparatorl
`(N=116)
`
`3 (3%)
`0 (0%)
`
`4 (3%)
`
`7 (6%)
`
`5 (4%)
`
`2 (2%)
`
`6<5%>
`0 (0%)
`
`8 (7%)
`
`1 (1%)
`
`Reference ID: 3664681
`
`10
`
`

`
`Adverse Reaction*
`
`Patients
`
`n (%)
`
` T
`
`CUBICIN 6 mg/kg
`Comparatorl
`(N=120)
`(N=116)
`Vascular disorders “
`Hypertension NOS
`7 (6%)
`3 (3%)
`
`* NOS, not otherwise specified.
`
`Comparator: vancomycin (1 g IV q12h) or an anti-staphylococcal sen1i-synthetic penicillin
`(i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 2 g IV q4h), each with initial low-dose
`gentan1icir1.
`
`The following reactions, not included above, were reported as possibly or probably drug-related
`in the CUBICIN-treated group:
`
`Blood and Lymphatic System Disorders .' eosinophilia, lymphadenopathy, thrombocythemia,
`thrombocytopenia
`
`Cardiac Disorders.‘ atrial fibrillation, atrial flutter, cardiac arrest
`
`Ear and Labyrinth Disorders.‘ tinnitus
`
`Eye Disorders.‘ vision blurred
`
`Gastrointestinal Disorders.‘ dry mouth, epigastric discomfort, gingival pain, hypoesthesia oral
`
`Infections and Infestations.‘ candidal infection NOS, vaginal candidiasis, fungemia, oral
`candidiasis, urinary tract infection fimgal
`
`Investigations.‘ blood phosphorous increased, blood alkaline phosphatase increased, INR
`increased, liver function test abnormal, alanine aminotransferase increased, aspartate
`aminotransferase increased, prothrombin time prolonged
`
`Metabolism and Nutrition Disorders.‘ appetite decreased NOS
`
`Musculoskeletal and Connective Tissue Disorders.‘ myalgia
`
`Nervous System Disorders.‘ dyskinesia, paresthesia
`
`Psychiatric Disorders .‘ hallucination NOS
`
`Renal and Urinary Disorders.‘ proteinuria, renal impairment NOS
`
`Skin and Subcutaneous Tissue Disorders.‘ pruritus generalized, rash vesicular
`
`Other Trials
`
`In Phase 3 trials of community-acquired pneumonia (CAP), the death rate and rates of serious
`cardiorespiratory adverse events were higher in CUBICIN-treated patients than in comparator-
`treated patients. These differences were due to lack of therapeutic effectiveness of CUBICIN in
`the treatment of CAP in patients experiencing these adverse events [see Indications and Usage
`(1.3)].
`
`Reference ID: 3664681
`
`11
`
`

`
`Laboratom Changes
`
`Complicated Skin and Skin Structure Infection Trials
`
`In Phase 3 cSSSI trials of CUBICIN at a dose of 4 mg/kg, elevations in CPK were reported as
`clinical adverse events in 15/534 (2.8%) CUBICIN-treated patients, compared with 10/558
`(1.8%) comparator-treated patients. Of the 534 patients treated with CUBICIN, 1 (0.2%) had
`symptoms of muscle pain or weakness associated with CPK elevations to greater than 4 times the
`upper limit of normal (ULN). The symptoms resolved within 3 days and CPK returned to
`normal within 7 to 10 days after treatment was discontinued [see Warnings and Precautions
`(5.2)]. Table 6 summarizes the CPK shifts from Baseline through End of Therapy in the cSSSI
`trials.
`
`Table 6. Incidence of CPK Elevations from Baseline during Therapy in Either the CUBICIN Treatment
`Group or the Comparator Treatment Group in Phase 3 cSSSI Trials
`
`All Patients
`
`Patients with
`Normal CPK at Baseline
`
`Change in CPK
`
`
`
`CUBICIN
`4 mg/kg
`(N=430)
`n
`
`%
`
`90.7
`
`390
`
`Comparator*
`(N=459)
`" o
`n
`
`CUBICIN
`4 mg/kg
`(N=374)
`%
`n
`
`Comparator*
`(N=392)
`%
`n
`
`91.1
`
`418
`
`91.2
`
`341
`
`91.1
`
`357
`
`f% N
`
`ote: Elevations in CPK observed in patients treated with CUBICIN or comparator were not clinically or
`statistically significantly different.
`
`*
`
`T
`
`Comparator: vancomycin (1 g IV ql 2h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin,
`oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV iI1 divided doses).
`
`ULN (Upper Limit of Normal) is defined as 200 U/L.
`
`S. aureus Bacteremia/Endocarditis Trial
`
`In the S. aureus bacteremia/endocarditis trial, at a dose of 6 mg/kg, 11/120 (9.2%) CUBICIN-
`treated patients, including two patients with baseline CPK levels >500 U/L, had CPK elevations
`to levels >500 U/L, compared with 1/116 (0.9%) comparator-treated patients. Of the 11
`CUBICIN-treated patients, 4 had prior or concomitant treatment with an HMG-CoA reductase
`inhibitor. Three of these 11 CUBICIN-treated patients discontinued therapy due to CPK
`elevation, while the one comparator-treated patient did not discontinue therapy [see Warnings
`and Precautions (5. 2)].
`
`Reference ID: 3664681
`
`

`
`6.2
`
`Post-Marketing Experience
`
`The following adverse reactions have been identified during postapproval use of CUBICIN.
`Because these reactions are reported voluntarily fiom a population of uncertain size, it is not
`always possible to estimate their fiequency reliably or establish a causal relationship to drug
`exposure.
`
`Immune System Disorders .' anaphylaxis; hypersensitivity reactions, including angioedema, drug
`rash with eosinophilia and systemic symptoms (DRESS), pruritus, hives, shortness of breath,
`difficulty swallowing, truncal erythema, and pulmonary eosinophilia [see Contraindications (4),
`Warnings and Precautions (5. 1)]
`
`Infections and Infestations.‘ Clostridium diflicile—associated diarrhea [see Warnings and
`Precautions (5. 6)]
`
`Musculoskeletal Disorders.‘ myoglobin increased; rhabdomyolysis (some reports involved
`patients treated concurrently with CUBICIN and HMG-CoA reductase inhibitors) [see Warnings
`and Precautions (5.2), Drug Interactions (7.1), and Clinical Pharmacology (I2.3)]
`
`Respiratory, Thoracic, and Mediastinal Disorders.‘ cough, eosinophilic pneumonia [see
`Warnings and Precautions (5. 3)]
`
`Nervous System Disorders.‘ peripheral neuropathy [see Warnings and Precautions (5. 4)]
`
`Skin and Subcutaneous Tissue Disorders.‘ serious skin reactions, including Stevens-Johnson
`syndrome and vesiculobullous rash (with or without mucous membrane involvement)
`
`Gastrointestinal Disorders.‘ nausea, vomiting
`
`7
`
`DRUG INTERACTIONS
`
`7.1
`
`HMG-CoA Reductase Inhibitors
`
`In healthy subjects, concomitant administration of CUBICIN and simvastatin had no effect on
`plasma trough concentrations of simvastatin, and there were no reports of skeletal myopathy [see
`Clinical Pharmacology (I2.3)].
`
`However, inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as
`muscle pain or weakness associated with elevated levels of creatine phosphokinase (CPK). In
`the Phase 3 S. aureus bacteremia/endocarditis trial, some patients who received prior or
`concomitant treatment with an HMG-CoA reductase inhibitor developed elevated CPK [see
`Adverse Reactions (6. 1)]. Experience with the coadrninistration of HMG-CoA reductase
`inhibitors and CUBICIN in patients is limited; therefore, consideration should be given to
`suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving CUBICIN.
`
`7.2
`
`Drug-Laboratory Test Interactions
`
`Clinically relevant plasma concentrations of daptomycin have been observed to cause a
`significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of
`International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are
`utilized for the assay. The possibility of an erroneously elevated PT/INR result due to

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket